Medix Biochemica invests $5m to expand its recombinant antigen capabilities

Medix Biochemica announced a Board-approved $5 million investment to expand its recombinant antigen and cell culture technology capabilities across its Espoo, Finland and St. Louis, Missouri facilities. The phased program — targeting 60+ commercially available recombinant antigen products by 2030 — ...